Pulse Journal Club Active Debates Trending Explore Researchers

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management | Synapse

March 25, 2020Open Access

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

Key Points

Key points are not available for this paper at this time.

Abstract

Most patients require a triplet regimen at relapse, with the choice of regimen varying with each successive relapse.

Read Full Paperexternally

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

S. Vincent Rajkumar (Wed,) studied this question.

synapsesocial.com/papers/69dadd807a67537a8ba3cb30 https://doi.org/https://doi.org/10.1002/ajh.25791

Ask AI

Helpful

Bookmark

Share

View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays2006 · 215 citations
2E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.2019 · 27 citations
3Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity1999 · 497 citations
4Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial2017 · 201 citations
5Autologous Transplantation and Maintenance Therapy in Multiple Myeloma2014 · 781 citations